Compare ECF & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | ORGO |
|---|---|---|
| Founded | 1986 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.7M | 166.0M |
| IPO Year | N/A | 2016 |
| Metric | ECF | ORGO |
|---|---|---|
| Price | $11.64 | $0.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 52.0K | ★ 601.6K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $37.55 |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $10.71 | $1.10 |
| 52 Week High | $13.85 | $7.08 |
| Indicator | ECF | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 18.64 |
| Support Level | $11.16 | N/A |
| Resistance Level | $11.67 | $2.69 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 2.74 | 0.00 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.